Targeted binding agents against B7-H1
Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.
1. An isolated antibody that specifically binds to B7-H1 having an amino acid sequence comprising:
a VH CDR1 having the amino acid sequence of SEQ ID NO: 63; and
a VH CDR2 having the amino acid sequence of SEQ ID NO: 64; and
a VH CDR3 having the amino acid sequence of SEQ ID NO: 65; and
a VL CDR1 having the amino acid sequence of SEQ ID NO: 68; and
a VL CDR2 having the amino acid sequence of SEQ ID NO: 69; and
a VL CDR3 having the amino acid sequence of SEQ ID NO: 70.
2. The antibody of claim 1 , wherein said antibody further comprises an Fc variant, wherein the Fc variant comprises at least one amino acid substitution selected from the group consisting of 234F, 235F, and 331S, as numbered by the EU index as set forth in Kabat.
3. The antibody of claim 1 , wherein said antibody comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 62 and a light chain variable domain having the amino acid sequence of SEQ ID NO: 67.
4. A nucleic acid molecule encoding the antibody of any one of claims 1 - 3 .
5. A cultured host cell transfected with a vector comprising the nucleic acid molecule of claim 4 .
6. An antibody produced by a method comprising, culturing said host cell of claim 5 , expressing an antibody encoded by said nucleic acid, and isolating said antibody from said culture.
7. A composition comprising the antibody of any one of claims 1 - 3 .
8. A pharmaceutical composition comprising the antibody of any one of claims 1 - 3 and a pharmaceutically acceptable carrier.